Further, clinical trials in large cohorts showed that larotrectinib (formerly known as LOXO-101) exhibited marked and durable antitumor activity in both adult and pediatric patients with TRK fusion positive cancer and locally advanced or metastatic solid tumors, regardless of patient age or tumor type, although resistance inevitably developed. This evidence concerns the gene NTRK1 and cancer.